Gene · 23091
Papers1,599
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 1,599
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance. | Sci Rep | 2023 | 37031216 | PubTator, text mining | PubMed |
| METTL14 is a chromatin regulator independent of its RNA N6-methyladenosine methyltransferase activity. | Protein Cell | 2023 | 37030005 | PubTator, text mining | PubMed |
| Comprehensive analyses of molecular features, prognostic values, and regulatory functionalities of m6A-modified long non-coding RNAs in lung adenocarcinoma. | Clin Epigenetics | 2023 | 37029420 | PubTator, text mining | PubMed |
| Single-cell mapping of N6-methyladenosine in esophageal squamous cell carcinoma and exploration of the risk model for immune infiltration. | Front Endocrinol (Lausanne) | 2023 | 37025404 | PubTator, text mining | PubMed |
| Effects of prenatal pesticide exposure on the fetal brain and placenta transcriptomes in a rodent model. | Toxicology | 2023 | 37019170 | PubTator, text mining | PubMed |
| Development a m6A regulators characterized by the immune cell infiltration in stomach adenocarcinoma for predicting the prognosis and immunotherapy response. | Aging (Albany NY) | 2023 | 37019148 | PubTator, text mining | PubMed |
| A prognostic model based on ferroptosis-related long non-coding RNA signatures and immunotherapy responses for non-small cell lung cancer. | Eur Rev Med Pharmacol Sci | 2023 | 37013777 | PubTator, text mining | PubMed |
| N6-methyladenosine modifications in maternal-fetal crosstalk and gestational diseases. | Front Cell Dev Biol | 2023 | 37009476 | PubTator, text mining | PubMed |
| Analysis of eight types of RNA modification regulators and their correlation with the prognosis in hepatocellular carcinoma. | Front Genet | 2023 | 37007958 | PubTator, text mining | PubMed |
| Epitranscriptomics in the development, functions, and disorders of cancer stem cells. | Front Oncol | 2023 | 37007137 | PubTator, text mining | PubMed |
| The role of RNA methyltransferase METTL3 in gynecologic cancers: Results and mechanisms. | Front Pharmacol | 2023 | 37007040 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A RNA methylation modification patterns and the immune microenvironment in osteoarthritis. | Front Immunol | 2023 | 37006311 | PubTator, text mining | PubMed |
| Expression patterns of eight RNA-modified regulators correlating with immune infiltrates during the progression of osteoarthritis. | Front Immunol | 2023 | 37006267 | PubTator, text mining | PubMed |
| Prognostic marker C3AR1 is associated with ovarian cancer cell proliferation and immunosuppression in the tumor microenvironment. | J Ovarian Res | 2023 | 37005667 | PubTator, text mining | PubMed |
| Identification of osteosarcoma m6A-related prognostic biomarkers using artificial intelligence: RBM15. | Sci Rep | 2023 | 37002245 | PubTator, text mining | PubMed |
| M6A-Related Long Non-Coding RNA Displays Utility in Predicting Prognosis, Portraying the Tumor Immune Microenvironment and Guiding Immunotherapy in Pancreatic Ductal Adenocarcinoma. | Vaccines (Basel) | 2023 | 36992083 | PubTator, text mining | PubMed |
| Identification of m6A-associated LncRNAs as predict factors for the immune infiltration and prognosis of thyroid cancer. | Ann Med | 2023 | 36974635 | PubTator, text mining | PubMed |
| Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation. | Nat Commun | 2023 | 36973285 | PubTator, text mining | PubMed |
| The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer. | Front Oncol | 2023 | 36969033 | PubTator, text mining | PubMed |
| Bioinformatics identification and experimental validation of m6A-related diagnostic biomarkers in the subtype classification of blood monocytes from postmenopausal osteoporosis patients. | Front Endocrinol (Lausanne) | 2023 | 36967763 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23091/papers?page=17